Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
about
Treatment of relapsed and refractory multiple myelomaA phthalimide derivative that inhibits centrosomal clustering is effective on multiple myelomaLenalidomide for the treatment of relapsed and refractory multiple myeloma.Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.Lenalidomide in multiple myeloma: current experimental and clinical data.Evidence-based mini-review: treatment options for patients with relapsed/refractory myeloma previously treated with novel agents and high-dose chemotherapy and autologous stem-cell transplantation.The role of bortezomib, thalidomide and lenalidomide in the management of multiple myeloma: an overview of clinical and economic information.How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions.Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and 'retreatment' approaches in the era of novel agents.Current strategies for treatment of relapsed/refractory multiple myeloma.Novel agents and new therapeutic approaches for treatment of multiple myeloma.Current treatment landscape for relapsed and/or refractory multiple myeloma.An update on the use of lenalidomide for the treatment of multiple myeloma.Concomitant MDS with isolated 5q deletion and MGUS: case report and review of molecular aspects.Trial Watch: Lenalidomide-based immunochemotherapy.
P2860
Q26749180-0DBE2110-D0B8-4790-9F70-643C9EEDE151Q28480621-48D125B4-2B46-4DE3-803C-5A3D94F0188CQ33403183-EDF62D76-4D63-4A44-A04E-F59960592810Q33404007-F0234F37-F49F-4C17-B0C7-4E7A2A7C4F35Q33973877-D55964F6-C404-4D29-AD29-EC332D826C9AQ34074803-97D579A8-4B2D-41FA-B37E-9887B01C41B5Q37829230-81E52699-3122-41E4-87C9-8E134E99FD61Q37851944-177A2BE3-CE9D-46EC-836B-3C473418B82CQ37862262-48A885C7-6F44-4739-8CAC-4A079B454D83Q37949201-4909D351-984D-48CC-85C2-A6AAF884F775Q38182683-8828D26B-83A8-44C5-B6E9-CFE58710E9DAQ38261677-0D38B52D-FFA5-4755-BF76-F2EC94BC6D8DQ38271032-3A04F561-5A4C-4571-A0BE-4D165AB73B36Q38545607-852218C0-AE3C-47B5-B537-97257A9AC1C0Q39013004-8560BB10-A580-4EEB-9E78-2E04B861EE8AQ42737828-0D271D95-634B-4191-B08A-F0158A4EEE8B
P2860
Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Lenalidomide, melphalan, predn ...... d/refractory multiple myeloma.
@ast
Lenalidomide, melphalan, predn ...... d/refractory multiple myeloma.
@en
type
label
Lenalidomide, melphalan, predn ...... d/refractory multiple myeloma.
@ast
Lenalidomide, melphalan, predn ...... d/refractory multiple myeloma.
@en
prefLabel
Lenalidomide, melphalan, predn ...... d/refractory multiple myeloma.
@ast
Lenalidomide, melphalan, predn ...... d/refractory multiple myeloma.
@en
P2093
P2860
P356
P1433
P1476
Lenalidomide, melphalan, predn ...... ed/refractory multiple myeloma
@en
P2093
A P Falcone
G Sanpaolo
M Boccadoro
M Crugnola
M Genuardi
M T Petrucci
V Federico
P2860
P2888
P304
P356
10.1038/LEU.2010.58
P577
2010-04-08T00:00:00Z
P6179
1022823970